| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Q/C Technologies, Inc.$3.89
-0.04 (-1%)
Market Cap
32.83 M
EPS
-21.21
P/E Ratio
-
Value Trade
1.36 M
SEC Financials
Q1 2026Dilution Risk
40%R&D Expenses
510.53 K
Operating CF
-3.29 M
Total Assets
38.29 M
Total Liabilities
14.60 M
Equity
20.72 M
D/E Ratio
12,345
-12.46 %
Week
7.18 %
1 Month
13.9 %
3 Month
26.67 %
6 Month
-99.97 %
5 Year
-100 %
All Time
Cash Data
Cash Position
12.97 M
Monthly Burn
1.10 M
Runway
10.7 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
250.05 K
52 Week Range
2.50 - 33.56
% held by Insiders
5.41 %
% held by Institutions
7.99 %
Enterprise Value
22.97 M
Total Shares
7.85 M
Short %
20.87 %
Float Shares
7.79 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in QCLS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Q/C Technologies, Inc. (QCLS) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
QCLS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QCLS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QCLS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
QCLS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
QCLS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
QCLSQ/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors New York, NY
Q/C Technologies announced the appointment of Chelsea Voss to its Board of Directors, effective January 20, 2026. Voss, a computer scientist at OpenAI, brings expertise in machine learning and AI systems development. The company is focusing on advancing its quantum-class laser processing units (qc-LPU) through partnerships aimed at enhancing photonic computing capabilities. However, Q/C Technologies must navigate risks related to product development and market conditions as it seeks to innovate in energy-efficient computing.
Read more →QCLSQuantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli New York
Q/C Technologies, Inc. (Nasdaq: QCLS) has announced the appointment of Martin Shkreli as a Strategic Advisor, adding depth to its advisory team. Shkreli, alongside advisor James Altucher, is expected to contribute insights into technology, industry contacts, and financial innovation. The company's quantum-class computing technology, which emphasizes optical advancements, aims to deliver exceptional performance while being energy efficient. Q/C's proprietary qc-LPU100 products are reported to outperform current GPUs and quantum computers significantly, utilizing 100 times less energy.
Read more →QCLSQ/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS" Licensed technology positions Company at forefront of new quantum-class computing paradigm New York, NY - Q/C Tec
Q/C Technologies, previously known as TNF Pharmaceuticals, has commenced trading on Nasdaq under the ticker symbol QCLS. The name change reflects the company's strategic pivot towards quantum-class computing, with exclusive rights to LightSolver's laser-based processing technology for cryptocurrency applications. This transition marks a significant milestone for the company, as it aims to leverage its innovative technology to provide high-speed computing solutions. Company leadership is optimistic about the potential for sustainable value for shareholders as they advance their first-mover strategy in the industry.
Read more →QCLSTNF Pharmaceuticals Announces Closing of $7 Million Private Placement Financing priced at a 44% premium to market Led by a top strategic investor with significant participation from existing stockholders New York, NY
TNF Pharmaceuticals has successfully closed a $7 million private placement financing of convertible preferred stock, priced at a 44% premium to market. This funding involved participation from TNF's largest strategic stockholder and other existing stockholders. The capital raised is earmarked to support key development milestones for TNF's newly licensed light-based computing accelerator technology. TNF's leadership expressed optimism about the financing, viewing it as a vote of confidence in their strategy and value proposition.
Read more →QCLSTNF Pharmaceuticals Secures Exclusive Global Rights to Innovative Light Speed Computing Accelerator for Use in Cryptocurrency Applications First light- and laser-based computing system designed to outperform quantum and
TNF Pharmaceuticals has secured exclusive global rights to a light-speed computing accelerator for cryptocurrency applications through a partnership with LightSolver. This technology, which aims to outperform conventional computing methods and reduce energy costs significantly, positions TNF for substantial growth in a burgeoning market. Notably, TNF plans to undergo a name change to reflect its new focus. The partnership is expected to unlock new efficiencies in blockchain technology and respond to the industry's demand for more effective computing solutions.
Read more →QCLSTNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market Prevail Partners, LLC investment priced at 40% premium to market Prevail InfoWorks, Inc. to act as Clinical Research Organization pa
TNF Pharmaceuticals has announced a strategic equity investment from Prevail Partners, LLC, priced at a 20% premium to its recent trading average. This investment will fully fund TNF Pharmaceuticals for its clinical trials over the next two years. Prevail InfoWorks will partner with TNF Pharmaceuticals as their clinical research organization for an upcoming Phase 2 study involving their lead drug candidate MYMD-1, targeting sarcopenia. The investment reflects confidence in MYMD-1's potential to transform treatment for autoimmune and inflammatory conditions, particularly in the context of aging.
Read more →QCLSMyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system Company plans mid-stage clin
MyMD Pharmaceuticals has officially rebranded to TNF Pharmaceuticals, Inc., reflecting its focus on TNF-alpha inhibition as a therapeutic target. The company plans to advance its lead drug, MYMD-1, into mid-stage clinical trials following positive Phase 2 results. MYMD-1 aims to offer a novel oral treatment option for inflammation-related conditions, distinguishing itself from existing injectable therapies. The stock will trade under the new symbol 'TNFA' on Nasdaq starting July 24, 2024.
Read more →QCLSMyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer Dr. Glass brings a 35-year career in life sciences with multiple d
MyMD Pharmaceuticals has appointed Dr. Mitchell Glass as President and Chief Medical Officer as the company advances its mid-stage clinical development. Dr. Glass boasts over 35 years of experience in the biopharmaceutical field and has a notable record of executing regulatory strategies and clinical trials. Along with Dr. Glass, Stephen Friscia has joined the board as an independent member, bringing valuable investment expertise. This leadership transition occurs following a successful Phase 2 study of MYMD-1, a treatment focusing on inflammatory diseases.
Read more →QCLSMyMD Pharmaceuticals Secures Strategic Investments Up to $42 Million in Two-Part Funding from New Strategic Investor and Existing Shareholders with Committed Closing of an Aggregate of $14 Million Up Front BALTIMORE
MyMD Pharmaceuticals has secured up to $42 million in two-part funding through private placements, with $14 million expected to close soon. A new strategic investor, PharmaCyte Biotech, led the commitment, along with contributions from existing shareholders. The funding will support the company's clinical programs, particularly the MYMD-1 drug for treating sarcopenia, which recently demonstrated positive Phase 2 trial outcomes. This capital infusion will provide stability for the next two years as the company advances its drug development efforts.
Read more →QCLSMyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing BALTIMORE, MD
MyMD Pharmaceuticals, Inc. announced that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing. The company had previously failed to meet this requirement due to its common shares trading below $1.00 for 30 consecutive business days. To address this issue, MyMD executed a 1-for-30 reverse stock split on February 14, 2024, which successfully raised the stock price above the minimum threshold. The company is committed to developing novel therapies aimed at age-related and autoimmune diseases.
Read more →QCLSMyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing Common Stock Will Begin Trading on Split-Adjusted Basis on
MyMD Pharmaceuticals announced a reverse stock split of its common stock at a ratio of 1-for-30 to maintain its Nasdaq listing. The split will become effective on February 14, 2024, reducing the number of outstanding shares from approximately 62.7 million to around 2.1 million. While the move aims to ensure compliance with listing standards, it raises concerns about the company's stock price stability and the future success of its clinical trials. The company is focused on developing therapies for age-related diseases and inflammatory conditions.
Read more →QCLSMyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis Company targets first quarter 2024 for trial initiation Potential to be first orally-administered TNF- inhibitor treatment f
MyMD Pharmaceuticals has announced plans to initiate a Phase 2 clinical trial for its drug MYMD-1, targeting rheumatoid arthritis (RA), with the trial expected to launch in Q1 2024 following FDA clearance of the IND application. MYMD-1 is positioned to be a significant advancement as the first orally-administered TNF-inhibitor, aiming to offer an effective alternative to current treatments. Preclinical studies indicate that MYMD-1 significantly reduced disease severity compared to existing therapies, with expectations for broader applications in autoimmune conditions. The trial will enroll approximately 60 patients to further assess the drug's efficacy and safety.
Read more →QCLSMyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD , Reduced Acute Inflammatory Pain - Supera-CBD eased heat-related pain due to inflammation quickly and provided long-lasting pain reli
MyMD Pharmaceuticals announced positive preclinical study results for Supera-CBD, a synthetic cannabidiol analog, demonstrating its ability to significantly reduce acute inflammatory pain within 60 minutes. The compound provided pain relief lasting up to five hours and indicated a targeted effect on specific pain pathways, potentially leading to fewer side effects than traditional opioid treatments. MyMD recently secured a Japanese patent for Supera-CBD as a new molecular entity, enhancing its commercial prospects. These findings add to the growing body of evidence supporting Supera-CBD's unique therapeutic profile in managing inflammatory pain.
Read more →QCLSMyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 - Company to share new positive, statistically significant results across Coho
MyMD Pharmaceuticals announced that it will present statistically significant Phase 2 data for its drug MYMD-1 at BioFuture 2023. The updated results indicate effectiveness in reducing inflammatory biomarkers associated with sarcopenia. The company's executives will discuss the research findings in anticipated presentations at the conference. Following these positive results, MyMD plans to seek FDA guidance for a Phase 3 clinical trial, potentially leading to the first FDA-approved medication for age-related muscle decline.
Read more →QCLSFDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis (RA) - Next-generation and first oral TNF- inhibitor, which completed P
MyMD Pharmaceuticals announced that the FDA has accepted its Investigational New Drug Application (IND) for the oral TNF-inhibitor MYMD-1, intended for treating rheumatoid arthritis (RA). The application is supported by positive Phase 2 results from a study on sarcopenia, demonstrating significant efficacy in reducing inflammatory markers. MYMD-1 differentiates itself by being the first oral TNF-inhibitor, potentially offering an important alternative to existing injectable therapies. The company plans to initiate a Phase 2 study in RA soon, marking a critical step forward in its development pipeline.
Read more →QCLSTranscript of MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Phase 2 Trial Update
MyMD Pharmaceuticals announced positive results from its Phase 2 trial for MYMD-1, an oral TNF-inhibitor designed to treat chronic inflammation and age-related frailty. The trial demonstrated statistically significant reductions in biomarkers associated with inflammation, indicating the drug's potential efficacy. MYMD-1 differentiates itself from traditional TNF inhibitors by offering a safer profile and targeting the root cause of inflammation. This development positions MyMD as a promising player in the growing field of immunotherapy.
Read more →QCLSMyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty - MYMD-1 significantly reduced serum levels of chro
MyMD Pharmaceuticals, Inc. announced positive topline results from its Phase 2 study of MYMD-1, an oral TNF- inhibitor for sarcopenia. The study achieved significant reductions in various inflammatory biomarkers and met both primary and secondary safety endpoints. MYMD-1, if approved, could become the first oral treatment for this age-related condition. The company plans to present the results to the FDA and advance further clinical trials.
Read more →QCLSMyMD Pharmaceuticals Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan - Currently, there are no FDA-approved treatments for sarcopenia
MyMD Pharmaceuticals has provided an update on its Phase 2 multi-center clinical trial for MYMD-1, aimed at treating chronic inflammation associated with sarcopenia and frailty. The trial is nearly complete, with only three patients left to be dosed. The company's Safety Review Committee reported no safety concerns with the already enrolled 30 patients. MYMD-1's development is significant given the absence of FDA-approved therapies for sarcopenia, highlighting its potential impact in addressing aging-related health challenges.
Read more →QCLSMyMD Pharmaceuticals and Charles River Present Positive Data for Next Generation, Oral TNF- Inhibitor MYMD-1 in Rheumatoid Arthritis Preclinical results showed MYMD-1 significantly reduced histopathological changes and t
MyMD Pharmaceuticals and Charles River Laboratories have announced promising preclinical data for MYMD-1, a next-generation oral TNF inhibitor targeting rheumatoid arthritis. The study revealed that MYMD-1 significantly reduced the severity of arthritis compared to a placebo, demonstrating impressive results across various clinical trial measures. MYMD-1 aims to transform treatment approaches for rheumatoid arthritis patients, providing a much-needed oral alternative to existing TNF inhibitors. The potential for MYMD-1 to cross the blood-brain barrier adds to its therapeutic promise.
Read more →QCLSMyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls BALTIMORE, MD
MyMD Pharmaceuticals has announced its membership in the LOT Network, an initiative designed to protect companies from litigation by patent trolls. By joining this international community of over 2,800 members, MyMD aims to safeguard its interests and intellectual property rights against frivolous lawsuits. This membership will allow MyMD to allocate more resources to its clinical development programs. The LOT Network provides its members with broad protection and peace of mind through a collective patent licensing agreement.
Read more →QCLSMyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical - DEA scientific review concludes Supera-CBD will not be classified as a regulated chemical
MyMD Pharmaceuticals announced that the U.S. Drug Enforcement Administration (DEA) has determined that Supera-CBD is not a controlled substance or listed chemical. This decision allows for unhindered drug development without the regulatory burden of scheduling. Supera-CBD is a synthetic cannabidiol analog believed to be 8000 times more potent as a CB2 agonist than traditional CBD. The company aims to explore its potential therapeutic benefits, including anti-inflammatory effects and applications in managing addiction and chronic pain.
Read more →QCLSMyMD Pharmaceuticals Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF- Inhibitor MYMD-1 at the Society of Toxicology 2023 Annual Meeting - Study results comparing the anti-inflammator
MyMD Pharmaceuticals announced that preclinical data for its oral TNF- inhibitor MYMD-1 will be presented at the Society of Toxicology 2023 Annual Meeting. The study, which was conducted with Charles River Laboratories, indicates significant reduction in inflammation in murine models of rheumatoid arthritis. MYMD-1 aims to transform treatment for TNF-related diseases with its selective design and is being assessed in Phase 2 studies for conditions like sarcopenia. This event highlights advancements in autoimmune therapies and the growing focus on new treatment modalities.
Read more →QCLSMyMD Announces $15 Million Offering with Existing Investors BALTIMORE
MyMD Pharmaceuticals has announced a $15 million offering through a registered direct offering with existing accredited and institutional investors. The funding is aimed to further the development of MYMD-1, a therapy for sarcopenia, and support the company's exploration of its use in rheumatoid arthritis. The offering includes convertible preferred stock and warrants, with expectations to close by February 23, 2023, pending customary conditions. This financial boost showcases investor confidence in MyMD's innovative approach to treating serious autoimmune conditions.
Read more →QCLSMyMD Pharmaceuticals to Present Data on Oral TNF-a Inhibitor MYMD-1 at the British Society for Immunology (BSI) Congress 2022 - Preclinical and early clinical studies of MYMD-1 , an oral, small-molecule, selective TNF- i
Pharmaceuticals to Present Data on TNF-a Inhibitor MYMD-1 at the British Society for Immunology (BSI) Congress 2022 Preclinical and early clinical studies of MYMD-1 , an oral, small-molecule, selective TNF- inhibitor, suggest future potential to disrupt the Rheumatoid Arthriti
Read more →QCLSMyMD Pharmaceuticals Announces Upcoming Presentation of Late-Breaking Data for MYMD-1 at the 2022 British Society for Immunology (BSI) Congress - Preclinical and early clinical studies of MYMD-1 , an oral, small-molecule
Pharmaceuticals Announces Upcoming Presentation of Late-Breaking Data for MYMD-1 at the 2022 British Society for Immunology (BSI) Congress MD - November 17, 2022 - MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage biopharmaceutical company d
Read more →QCLSMyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1 in Peer-Reviewed Journal Data Research MYMD-1 demonstrated favorable safety and tolerability profile across multiple doses, w
Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1 in Peer-Reviewed Journal Data Research demonstrated favorable safety and tolerability profile across multiple doses, with no clinically relevant adverse events, supporting advancement of t
Read more →QCLSMyMD Pharmaceuticals Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data anticipated in Q4 of 2022 BALTIMORE, MD
Pharmaceuticals Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan data anticipated in Q4 of 2022 MD - September 20, 2022 - MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"),
Read more →QCLSMYMD PHARMACEUTICALS RECEIVES GRANT FROM EUROPEAN PATENT OFFICE FOR SUPERA-CBD COMPOUND ALLOWED CLAIMS COVER SUPERA-CBD AS A
PHARMACEUTICALS RECEIVES GRANT FROM EUROPEAN OFFICE FOR SUPERA-CBD COMPOUND CLAIMS COVER SUPERA-CBD AS A NEW MOLECULAR ENTITY AND PHARMACEUTICAL FORMULATIONS CONTAINING THE COMPOUND MD. - August 30, 2022 - MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD"), a clinical stage p
Read more →QCLSData Showing MyMD Pharmaceuticals' MYMD-1 May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences Study of oral TNF- inhibitor MYMD-1 demonstrates significant improvements in lifes
Showing MyMD Pharmaceuticals' MYMD-1 May Extend Life and Improve Health Published in the Journal of Gerontology: of oral TNF- inhibitor MYMD-1 demonstrates significant improvements in lifespan and maintenance of health characteristics compared to rapamycin MD. - August 3, 2022
Read more →QCLSMyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Sarcopenia trial shows no evidence of toxicity or safety issues and patients were
Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan trial shows no evidence of toxicity or safety issues and patients were enrolled in the next higher dose of MYMD-1 MD. - July 26, 2022 - MyMD Ph
Read more →QCLSMyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions Bascom Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News
Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions Palmer Eye Institute ranked the #1 eye hospital in the United States for 20 years in a row by U.S. News & World Report MD. - July 12, 2022 - MyMD Pharmaceuticals, Inc. (Nasd
Read more →QCLSMyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data expected in second half of 2022 BALTIMORE, MD.
Pharmaceuticals Advances Phase 2 Multi-Center Clinical of MYMD-1 as a Therapy for Delaying Aging and Extending data expected in second half of 2022 MD. - June 21, 2022 - MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical compa
Read more →QCLSMyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis MyMD seeks to disrupt the $31 billion global ma
Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis seeks to disrupt the $31 billion global market for rheumatoid arthritis (RA) drug therapies with MYMD-1, which
Read more →QCLSMyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan Efficacy data from fully funded Phase 2 trial is expected in first half of 202
Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan data from fully funded Phase 2 trial is expected in first half of 2022 MD. - February 23, 2022 - MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (
Read more →QCLSMyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Phase 1 dose-ranging study results meet primary endpoints Drug demonstrates statisticall
Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Phase 1 dose-ranging study results meet primary endpoints Drug demonstrates statistically significant efficacy in reducing levels of the root cause
Read more →QCLSMyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia Expands intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S. patents related to aging and
Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia intellectual property portfolio for lead drug candidate MYMD-1 to 3 U.S. patents related to aging and extending healthy lifespan, 16 MD. - January 5, 2022 - MyMD Pharmaceuti
Read more →QCLSMyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan Believed to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for d
Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan to be the only IND application ever cleared by the FDA for a Phase 2 trial of a patented drug for delaying aging 2 trial recruiting begins immediately; efficacy data expe
Read more →QCLSMyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation MyMD's lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with auto
Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation lead drug candidate, MYMD-1, is being developed to target aging and related diseases along with autoimmune diseases including rheumatoid MD. - October 26, 2021 - MyMD Ph
Read more →QCLSMyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 MyMD is pursuing high value opportunities in a massiv
Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 is pursuing high value opportunities in a massive healthcare market with no known competing FDA-approved drugs for t
Read more →QCLSMyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 MyMD to launch two simultaneous Phase 2 trials during the current quarter to
Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials the Benzinga Rising Stars: Catalytic Small Cap Growth to launch two simultaneous Phase 2 trials during the current quarter study MYMD-1's function in extending healthy lifespan and treating MD. - October 5, 2021 - MyMD
Read more →QCLSMyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD Data indicates potential of drug candidate to deliver an extremely potent therapeutic
Pharmaceuticals Announces New Data Demonstrating 8,000 Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose data will be presented at the 4th A
Read more →QCLSMyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan Key objective of the trial is to reduce levels of the protein that causes inflammation and
Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan objective of the trial is to reduce levels of the protein that causes inflammation and activates aging, TNF- , in the blood is designed to become the firs
Read more →QCLSAkers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger Shares to commence trading on the Nasdaq Capital Market on
Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol "MYMD" Upon Closing, the Combined Company will focus on developing and commercializing novel immuno
Read more →QCLSREMINDER: Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals Baltimore, Maryland
Akers Biosciences Schedules Conference Call to Discuss Merger with MyMD Pharmaceuticals Maryland, November 18, 2020 (BUSINESSWIRE) - MyMD Pharmaceuticals, Inc. ("MyMD") and Akers Biosciences, Inc. ("Akers") (NASDAQ: AKER) jointly announced a definitive merger agreement last wee
Read more →QCLSAkers Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement Immunotherapies focused on age-related disorders and autoimmune diseases entering Phase 2 clinical trials Lead molecule MYMD-1 inhibits producti
Biosciences and MyMD Pharmaceuticals Sign Definitive Merger Agreement Immunotherapies focused on age-related disorders and autoimmune diseases entering Phase 2 clinical trials Lead molecule MYMD-1 inhibits production of tumor necrosis factor alpha (TNF- ), a cell signaling p
Read more →QCLSAkers Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results Thorofare, New Jersey
Biosciences and Premas Biotech Announce SARS CoV-2 Positive Proof of Concept Results New Jersey, August 27, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced with its partner, Premas Biotech, po
Read more →QCLSExecution Version
Howard R. Yeaton, Chief Executive Officer letter agreement (this "Agreement") constitutes the agreement between Akers Biosciences, Inc. (the "Company") and H.C. Wainwright & Co., LLC ("Wainwright"), that Wainwright shall serve as the exclusive agent, advisor or underwriter in
Read more →QCLSAkers Biosciences and Premas Biotech Announce Initiation of Animal Studies Company intends to cease focus on screening and testing products business Thorofare, New Jersey
Biosciences and Premas Biotech Announce Initiation of Animal Studies intends to cease focus on screening and testing products business New Jersey, July 7, 2020/ -- Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, tod
Read more →QCLSAkers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Thorofare, New Jersey
Biosciences Closes $4.8 Million Registered Direct Offering At-the-Market under Nasdaq Rules New Jersey, May 18, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously a
Read more →QCLSAkers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Thorofare, New Jersey
Biosciences Announces $4.8 Million Registered Direct Offering At-the-Market under Nasdaq Rules New Jersey, May 14, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it has entered into def
Read more →QCLSAkers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP Thorofare, New Jersey
Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP New Jersey, May 14, 2020/ -- Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Prem
Read more →QCLSAkers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens Thorofare, New Jersey
Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens New Jersey, April 8, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Bi
Read more →QCLSAkers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19 Successfully obtained clones for all three selected Coronavirus Antigens Thorofare, New Jersey
Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19 Thorofare, New Jersey, April 06, 2020 (GLOBE NEWSWIRE) - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that
Read more →QCLSAkers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech Established D-Crypt platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candi
Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech Established D-Crypt platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for Coronavirus Current Regulatory environment could le
Read more →QCLSAkers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation Thorofare, New Jersey
Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation New Jersey, January 17, 2020/ - Akers Biosciences, Inc. (the "Company") (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement
Read more →QCLSAkers Biosciences Announces Q3 2018 Earnings Sales of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value THOROFARE, N.
Biosciences Announces Q3 2018 Earnings of Flagship PIFA Heparin PF/4 Rapid Assay Products Up 16% over Q3 2017; Company Continuing to Evaluate Strategic Alternatives to Maximize Shareholder Value N.J., November 15, 2018 (GLOBE NEWSWIRE) - Akers Biosciences, Inc. (NASDAQ: AKER)
Read more →QCLSAkers Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update THOROFARE, N.J.
Biosciences Announces a Leadership Change, Strategic Update, Legal Settlement and an AIM Update N.J., October 8, 2018 (GLOBE NEWSWIRE) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, an
Read more →QCLSAkers Biosciences Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement THOROFARE, N.J.
Biosciences Granted 180-Day Extension by Nasdaq Meet Minimum Bid Price Requirement N.J., May 30, 2018 (Marketwired) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, on M
Read more →QCLSAkers Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq THOROFARE, N.J.
Biosciences Receives Notice of Delinquent Form 10-Q Filing from Nasdaq N.J., May 25, 2018 (Marketwired) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that it received a noti
Read more →QCLSAkers Biosciences Announces Closing of $6,900,000 Public Offering THOROFARE, N.J
Biosciences Announces Closing of $6,900,000 Public Offering N.J, Dec. 21, 2017 (GLOBE NEWSWIRE) - Akers Biosciences, Inc. (NASDAQ:AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today announces the closing of its previou
Read more →QCLSAkers Biosciences Prices $6,000,000 Public Offering THOROFARE, N.J
Biosciences Prices $6,000,000 Public Offering N.J, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today announces the pricing of an underwritten public o
Read more →QCLSJanuary 2017 This announcement contains inside information Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health informat
announcement contains inside information Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a developer of rapid health information technologies, announces that, further to the public offering announced on January 10, 2017 (the "Offering"), Joseph G
Read more →QCLSAkers Biosciences Announces Pricing of Public Offering of 1,667,000 Shares and 833,500 Warrants THOROFARE, N.J.
Akers Biosciences Announces Pricing of 1,667,000 Shares and 833,500 Warrants THOROFARE, N.J., January 9, 2017 (Marketwired) - Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, today annou
Read more →QCLSAkers Biosciences Appoints Dr. Raza Bokhari as Non-executive Director THOROFARE, N.J.
Biosciences Appoints Dr. Raza Bokhari as Non-executive Director N.J., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ:AKER) (AIM:AKR.L), (the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, is
Read more →QCLSAkers Biosciences Appoints Former Congressman Rob Andrews to the Board THOROFARE, N.J.
Biosciences Appoints Former Congressman Rob Andrews to the Board N.J. June 30, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ("Akers Bio" or the "Company"), a medical device company focused on reducing the cost of healthcare through faster, easie
Read more →QCLSAkers Biosciences Announces Joint Venture to Market Rapid Diagnostic Tests in China Akers Biosciences, Inc.
Announces Joint Venture to Market Rapid Diagnostic Tests in China Inc. October 23, 2014 8:17 AM GlobeNewswire N.J., Oct. 23, 2014 (GLOBE NEWSWIRE) - Akers Biosciences, Inc. (AKER) (AKR.L) (the "Company" or "Akers"), a leading designer and manufacturer of rapid diagnostic scre
Read more →QCLSAkers Biosciences Co-Founder and Executive Chairman to Assume Duties of President &
Akers Biosciences Co-Founder and Executive Chairman to Assume Duties of President & CEO THOROFARE, N.J., March 12, 2014 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (LSE:AKR) (Nasdaq:AKER), (the "Company" or "ABI"), a leading designer and manufacturer of rapid diagnostic scree
Read more →Competitive Position
How QCLS ranks across every disease it competes inCompetitive Position is a premium feature
See how QCLS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial